Chronic GHRP-6 and MK-677 Infusion Desensitizes Arcuate Nucleus GH Secretory Response in Rats
Background
Growth hormone (GH) secretion is governed by hypothalamic neuroendocrine circuitry, primarily the balance between stimulatory GHRH and inhibitory somatostatin neurons in the arcuate and periventricular nuclei. GH secretagogues such as GHRP-6 and MK-677 potentiate GH release both at the anterior pituitary somatotrope level and via hypothalamic circuitry, acutely activating neurons in the arcuate nucleus as evidenced by Fos protein induction. Prolonged administration of these secretagogues has been reported to sustain enhanced pulsatile GH secretion, but the underlying neurobiological mechanisms — particularly how chronic exposure reshapes GHRH, NPY, and somatostatin gene expression — remained poorly characterized. Understanding whether repeated GH secretagogue exposure leads to central desensitization is critical for optimizing therapeutic and investigational dosing protocols.
Study Design
Male rats received chronic intracerebroventricular infusion of GH secretagogues (either GHRP-6 or MK-677) for 5 days via central cannula, with saline-infused animals serving as controls. Following the infusion period, animals were challenged with acute systemic administration of GH secretagogues to test retained responsiveness. Primary endpoints were Fos protein expression and in situ hybridisation-measured mRNA levels for GHRH, neuropeptide Y (NPY), and somatostatin in the arcuate and periventricular nuclei. Plasma GH secretion in response to acute challenge was also measured to assess functional output.
Results
After 5 days of chronic central GH secretagogue infusion, there was no sustained expression of Fos protein in the arcuate nucleus during the infusion period, indicating the absence of ongoing neuronal activation. When these chronically infused animals were challenged with an acute systemic dose of GH secretagogues, no significant induction of Fos expression was observed in the arcuate nucleus — a response that would normally be robust in naive animals. GH secretion in response to the acute challenge was greatly attenuated, collectively reflecting a loss of functional responsiveness to GH secretagogues at the central level. In situ hybridisation revealed that GHRH, NPY, and somatostatin mRNA levels in the arcuate nucleus were not significantly different from saline-infused controls, suggesting transcriptional regulation in the arcuate itself was not the primary driver of desensitization.
Somatostatin mRNA levels in the periventricular nucleus were significantly elevated in GH secretagogue-infused rats compared to saline controls — implicating this distinct nucleus as a key mediator of the desensitized state.
Together these findings dissociate the arcuate transcriptional response from the functional desensitization, pointing to periventricular somatostatin upregulation as a plausible suppressive mechanism.
Key Findings
- Chronic 5-day central infusion abolished Fos induction in the arcuate nucleus following acute GH secretagogue challenge
- GH secretion in response to acute challenge was greatly attenuated after chronic central infusion
- Arcuate nucleus GHRH, NPY, and somatostatin mRNA levels were not significantly changed vs. saline controls
- Periventricular nucleus somatostatin mRNA was significantly elevated in GH secretagogue-infused rats vs. controls
- Findings indicate functional loss of central GH secretagogue responsiveness without arcuate transcriptional changes
Why It Matters
Continuous or prolonged central exposure to GH secretagogues drives desensitization, not sensitization — a direct challenge to the assumption that chronic dosing linearly amplifies GH output. For peptide users and clinicians considering sustained GHRP-6 or MK-677 protocols, this data supports the mechanistic basis for cycling or pulsatile dosing rather than continuous infusion to preserve hypothalamic responsiveness. The finding that periventricular somatostatin tone rises with chronic exposure suggests that somatostatin-blocking strategies or dose holidays could theoretically restore sensitivity. Clinical translation requires caution: central infusion in rats is mechanistically informative but does not map directly to subcutaneous or oral dosing pharmacokinetics used in humans, so the desensitization threshold in practical protocols remains undefined.
